Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Sci Rep. 2024 Mar 6;14(1):5508. doi: 10.1038/s41598-024-55989-4.
The ongoing vaccination efforts and exposure to endemic and emerging coronaviruses can shape the population's immunity against this group of viruses. In this study, we investigated neutralizing immunity against endemic and emerging coronaviruses in 200 Tanzanian frontline healthcare workers (HCWs). Despite low vaccination rates (19.5%), we found a high SARS-CoV-2 seroprevalence (94.0%), indicating high exposure in these HCWs. Next, we determined the neutralization capacity of antisera against human coronavirus NL63, and 229E, SARS-CoV-1, MERS-CoV and SARS-CoV-2 (including Omicron subvariants: BA.1, BQ.1.1 and XBB.1.5) using pseudovirus neutralization assay. We observed a broad range of neutralizing activity in HCWs, but no neutralization activity detected against MERS-CoV. We also observed a strong correlation between neutralizing antibody titers for SARS-CoV-2 and SARS-CoV-1, but not between other coronaviruses. Cross-neutralization titers against the newer Omicron subvariants, BQ.1.1 and XBB.1.5, was significantly reduced compared to BA.1 and BA.2 subvariants. On the other hand, the exposed vaccinated HCWs showed relatively higher median cross-neutralization titers against both the newer Omicron subvariants and SARS-CoV-1, but did not reach statistical significance. In summary, our findings suggest a broad range of neutralizing potency against coronaviruses in Tanzanian HCWs with detectable neutralizing immunity against SARS-CoV-1 resulting from SARS-CoV-2 exposure.
在坦桑尼亚,正在进行的疫苗接种工作以及对地方性和新兴冠状病毒的接触,可能会影响该人群对这组病毒的免疫力。在这项研究中,我们调查了 200 名坦桑尼亚一线医护人员(HCWs)对地方性和新兴冠状病毒的中和免疫情况。尽管疫苗接种率较低(19.5%),但我们发现 SARS-CoV-2 的血清阳性率很高(94.0%),表明这些 HCWs 中有很高的暴露率。接下来,我们使用假病毒中和试验测定了抗人冠状病毒 NL63 和 229E、SARS-CoV-1、MERS-CoV 和 SARS-CoV-2(包括奥密克戎亚变种:BA.1、BQ.1.1 和 XBB.1.5)的中和能力。我们观察到 HCWs 中存在广泛的中和活性,但未检测到针对 MERS-CoV 的中和活性。我们还观察到 SARS-CoV-2 和 SARS-CoV-1 的中和抗体滴度之间存在很强的相关性,但其他冠状病毒之间没有相关性。与 BA.1 和 BA.2 亚变种相比,针对较新的奥密克戎亚变种 BQ.1.1 和 XBB.1.5 的交叉中和滴度显著降低。另一方面,暴露后接种疫苗的 HCWs 对两种新的奥密克戎亚变种和 SARS-CoV-1 的中位交叉中和滴度相对较高,但未达到统计学意义。总之,我们的研究结果表明,坦桑尼亚 HCWs 对冠状病毒具有广泛的中和效力,并且由于 SARS-CoV-2 的暴露而检测到针对 SARS-CoV-1 的中和免疫。